Keyword: Concert Pharmaceuticals

Vertex, Concert orchestrate $250M phase 2 CF drug deal

Vertex could pay out as much as $250 million to gain full access to Concert Pharmaceuticals’ midstage cystic fibrosis candidate CTP-656, a tweaked version of its own Kalydeco, as it eyes combo uses that target the underlying causes of the fatal disease.